Zai Lab (ZLAB) Expected to Release Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.5642) per share and revenue of $108.83 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. The company had revenue of $106.31 million during the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. On average, analysts expect Zai Lab to post ($2.37) EPS for the current fiscal year and ($2.36) EPS for the next fiscal year.

Zai Lab Price Performance

ZLAB stock opened at $21.67 on Tuesday. Zai Lab has a 1 year low of $15.96 and a 1 year high of $27.50. The company’s 50-day moving average is $24.85 and its 200-day moving average is $20.97.

Insiders Place Their Bets

In other Zai Lab news, Director William Lis sold 8,506 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the sale, the director owned 41,931 shares in the company, valued at $1,048,275. This trade represents a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 9,385 shares of company stock worth $235,145 in the last quarter. Company insiders own 4.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZLAB shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research report on Tuesday, October 27th. Wall Street Zen raised Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Citigroup raised their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Zacks Research raised shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zai Lab has an average rating of “Moderate Buy” and an average target price of $37.25.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.